Literature DB >> 24763695

[Interdisciplinary treatment of soft tissue sarcoma of the extremities].

J Jakob1, T Henzler, B Kasper, A Marx, P Hohenberger.   

Abstract

Soft tissue sarcomas are a rare and heterogeneous group of tumors. Surgery clearly remains the standard therapy of non-metastatic soft tissue sarcoma. A pretreatment biopsy is necessary to determine the histology and grade of soft tissue sarcomas and to diagnose entities that can be treated by targeted therapies, such as dermatofibrosarcoma protuberans or alveolar soft tissue sarcoma once they are in a metastatic stage. Nevertheless, locally advanced disease requires multimodal treatment and interdisciplinary treatment decisions. Limb sarcoma of borderline resectability (encasement of vessels, invasion of joints or close proximity to motor nerves) may profit from isolated limb perfusion with recombinant tumor necrosis factor and melphalan. Preoperative chemotherapy may be applied in locally advanced high grade tumors when clear resection margins are difficult to achieve. Deep wave hyperthermia has proven to be a useful addition to systemic chemotherapy in such a neoadjuvant setting. Also preoperative radiation therapy has proven to be effective in controlling locally advanced sarcoma despite higher perioperative morbidity which pays off in the long run by better limb function. Postoperative adjuvant external beam irradiation therapy with the best available technique is recommended for any tumor larger than 5 cm with (FNLCC) grades 2 and 3 (American Joint Committee on Cancer stage IIb/III). Given all these therapeutic options, it is absolutely crucial that interdisciplinary decision-making starts early in the therapeutic process. Patients are often seen first by the surgeon. For an optimal treatment surgeons need to know the efficacy and toxicity of the multimodal treatment options described.

Entities:  

Mesh:

Year:  2014        PMID: 24763695     DOI: 10.1007/s00104-013-2689-3

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  37 in total

1.  Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas.

Authors:  Jan P Deroose; Alexander M M Eggermont; Albertus N van Geel; Jacobus W A Burger; Michael A den Bakker; Johannes H W de Wilt; Cornelis Verhoef
Journal:  J Clin Oncol       Date:  2011-09-19       Impact factor: 44.544

Review 2.  Radiotherapy for management of extremity soft tissue sarcomas: why, when, and where?

Authors:  Rick L M Haas; Thomas F Delaney; Brian O'Sullivan; Ronald B Keus; Cécile Le Pechoux; Patricia Olmi; Jan-Peter Poulsen; Beatrice Seddon; Dian Wang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-04-18       Impact factor: 7.038

Review 3.  Translocation-related sarcomas.

Authors:  Fredrik Mertens; Cristina R Antonescu; Peter Hohenberger; Marc Ladanyi; Piergiorgio Modena; Maurizio D'Incalci; Paolo G Casali; Massimo Aglietta; Thor Alvegård
Journal:  Semin Oncol       Date:  2009-08       Impact factor: 4.929

4.  [Soft tissue sarcoma : resection and plastic reconstruction].

Authors:  H U Steinau; L Steinsträsser; J Hauser; D Tilkorn; I Stricker; A Daigeler
Journal:  Chirurg       Date:  2012-07       Impact factor: 0.955

5.  Results of surgery and multimodal therapy for patients with soft tissue sarcoma invading to vascular structures.

Authors:  P Hohenberger; J R Allenberg; P M Schlag; P Reichardt
Journal:  Cancer       Date:  1999-01-15       Impact factor: 6.860

6.  Surgical margins and reresection in the management of patients with soft tissue sarcoma using conservative surgery and radiation therapy.

Authors:  Gunar K Zagars; Matthew T Ballo; Peter W T Pisters; Raphael E Pollock; Shreyaskumar R Patel; Robert S Benjamin
Journal:  Cancer       Date:  2003-05-15       Impact factor: 6.860

7.  Conformity to clinical practice guidelines, multidisciplinary management and outcome of treatment for soft tissue sarcomas.

Authors:  I Ray-Coquard; P Thiesse; D Ranchère-Vince; F Chauvin; J-Y Bobin; M-P Sunyach; J-P Carret; B Mongodin; P Marec-Bérard; T Philip; J-Y Blay
Journal:  Ann Oncol       Date:  2004-02       Impact factor: 32.976

8.  Evaluation of 47 soft tissue sarcoma resection specimens after isolated limb perfusion with TNF-alpha and melphalan: histologically characterized improved margins correlate with absence of recurrences.

Authors:  Florian Grabellus; Corinna Kraft; Sien-Yi Sheu; Peter Ebeling; Sebastian Bauer; Sven Lendemans; Kurt W Schmid; Georg Taeger
Journal:  Ann Surg Oncol       Date:  2009-01-06       Impact factor: 5.344

9.  Isolated limb perfusion with rhTNF-alpha and melphalan for locally recurrent childhood synovial sarcoma of the limb.

Authors:  Peter Hohenberger; Per Ulf Tunn
Journal:  J Pediatr Hematol Oncol       Date:  2003-11       Impact factor: 1.289

10.  Clinicians' adherence versus non adherence to practice guidelines in the management of patients with sarcoma: a cost-effectiveness assessment in two European regions.

Authors:  Lionel Perrier; Alessandra Buja; Giuseppe Mastrangelo; Antonella Vecchiato; Paolo Sandonà; Françoise Ducimetière; Jean-Yves Blay; François Noël Gilly; Carole Siani; Pierre Biron; Dominique Ranchère-Vince; Anne-Valérie Decouvelaere; Philippe Thiesse; Christophe Bergeron; Angelo Paolo Dei Tos; Jean-Michel Coindre; Carlo Riccardo Rossi; Isabelle Ray-Coquard
Journal:  BMC Health Serv Res       Date:  2012-03-28       Impact factor: 2.655

View more
  2 in total

1.  Musculoskeletal Soft-Tissue Sarcoma: Quality Assessment of Initial MRI Reports Shows Frequent Deviation from ESSR Guidelines.

Authors:  Sebastian Weiss; Alexander Korthaus; Nora Baumann; Jin Yamamura; Alexander S Spiro; Andreas M Lübke; Karl-Heinz Frosch; Carsten Schlickewei; Matthias Priemel
Journal:  Diagnostics (Basel)       Date:  2021-04-14

Review 2.  Soft Tissue Coverage of the Lower Limb following Oncological Surgery.

Authors:  Christine Radtke; Martin Panzica; Khaled Dastagir; Christian Krettek; Peter M Vogt
Journal:  Front Oncol       Date:  2016-01-13       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.